News
Femtech start-ups hit record high in France, report finds
More than 90 per cent of the femtech start-ups in France were co-founded by women, new findings have shown
The number of femtech companies incorporated in France jumped by almost 22 per cent in 2024, a new report has found.
The report, published by Femtech France in collaboration with the Paris-based consulting firm Wavestone, found that there were 140 French femtech start-ups listed as of April 20, almost 22 per cent more than in 2023.
The three healthcare categories most addressed by these start-ups were menstrual health, general health, followed by a tie on chronic pathologies and pelvic health.
According to the report, 57 per of start-ups were in the wellness sector, and 43 per cent in the health sector, meaning that the product/service is part of a care pathway.
Among the companies surveyed, 94 per cent were co-founded by women and 33 per cent had a healthcare professional on the founding team. The majority of these companies (60 per cent) were created between 2021 and 2023.
Geographically, the start-ups surveyed were mainly from the Paris region (52 per cent), followed by Auvergne-Rhône-Alpes, Nouvelle-Aquitaine and Pays de la Loire (seven per cent).
The findings showed the average cumulative revenue in 2023 for the start-ups surveyed amounted to €42.8m. More than 75 per cent of the businesses had a product on the market, and of these, 76 per cent were generating sales.
The market-leading start-ups, according to the survey, were Perifit and Fizimed, which both make perineal devices and breast pumps, followed by Apricity, a virtual fertility clinic.
The average amount of funds raised by start-ups surveyed since their creation was €950,000.
Forty per cent of companies have been financed since their creation, mainly through fundraising (59 per cent), self-financing (34 per cent) and grants and subsidies (three per cent).
Among the biggest fundraisers in 2023 were Sonio ultrasound software (€13m), Womed treatments for complex uterine pathologies (€6m), and Sorella medical offices dedicated to women’s health (€5m).
France was the main market for 87 per cent of the start-ups surveyed, the report found.
Among the market trends observed by Femtech France, women’s health in the workplace was a strong theme. The challenges, the report noted, were affordability, carbon footprint and funding.
Juliette Mauro, President of Femtech France, said: “Our report takes an in-depth look at the state of the industry in France.
“The presence of series A and series B companies on the femtech market in France and Europe should motivate the financial institutions to create dedicated femtech funds to support the development and growth of these structures.”
Delphine Moulu, co-founder and managing director of FemTech France, added: “The femtech industry lacks data so it’s important for us to publish this annual report on the French Femtech market.
“Precise and up to date numbers are key for all the stakeholders – founders, investors but also public authorities.”
To receive the Femtech World newsletter, sign up here.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Wellness3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur6 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health







4 Comments